Mandate

VINGE ADVISES INDUSTRIFONDEN IN CONNECTION WITH INVESTMENT IN INRIVER

August 14, 2013

Vinge has advised Industrifonden which, together with Zobito, has invested a total of SEK 20 million in the Malmö-based software company, inRiver. inRiver’s software helps companies to manage product information in a simpler and more expeditious manner. The funds will be used to finance inRiver’s future international expansion in the US and other countries.

inRiver’s software allows customers to quickly and efficiently collect all product information by uploading texts in different languages, pictures of products and films in inRiver’s software – a process which is called Product Information Management (PIM). Products are placed on the market more quickly with PIM and the information can thereafter be quickly distributed and easily adapted for marketing and sales materials via various sales channels.

The company has expanded significantly in the last few years and has managed to achieve a leading position in the Nordic region in its field with customers such as Stadium, Lindex, Fazer, Gant, Haléns and Byggmax. iRiver has now commenced its international expansion by, among other things, establishing subsidiaries in the US and the Netherlands.

Vinge’s team consisted primarily of partner Johan Larsson and associates Karl Hahtovirta and Philip Watson.   

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026